Japanese Pharma Sea Change: U.S. Development Takes Focus Over Licensing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Japanese pharma firms are changing the long-standing practice of out-licensing products in the U.S., with maturing U.S. operations now directly developing more than a dozen drugs in or near Phase III.
You may also be interested in...
Replidyne faropenem NDA in 2005
Replidyne will file an NDA for its oral antibiotic faropenem "later this year," the firm announces at the Biotechnology Industry Organization's investor conference Feb. 24. Replidyne is touting faropenem as having a broad spectrum of activity comparable to the quinolones with a safety profile similar to the beta-lactam class. The company believes the antibiotic market size will allow the drug to generate significant sales with a relatively small share. Bayer in-licensed faropenem from Daiichi Suntory but dropped it in 2002; Replidyne acquired rights in August 2004 (1Pharmaceutical Approvals Monthly September 2004, p. 16)...
Daiichi, Sankyo Deal Will Fend Off Foreign Competition In Japan, Build In U.S.
Daiichi/Sankyo merger will build domestic position, broaden U.S. market penetration. Daiichi Sankyo will be the second largest Japanese pharmaceutical company based on domestic sales. Combined global sales force is 2,200 reps, with plans to expand. U.S. sales force is 850 reps. Integration should be complete by April 2007